Palvella Therapeutics, Inc. (PVLA) — 8-K Filings

8-K Filings (21)

• 8-K Filing — May 7, 2026
• 8-K Filing — Apr 7, 2026
• 8-K Filing — Mar 31, 2026
• Palvella Therapeutics Files 8-K — Dec 15, 2025 Risk: low
  On December 15, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statement
• Palvella Therapeutics Files 8-K on Financials — Nov 10, 2025 Risk: low
  Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Cond
• 8-K Filing — Nov 5, 2025
• Palvella Therapeutics, Inc. Files 8-K for Name Change — Sep 24, 2025 Risk: low
  On September 24, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily serves as a notification of
• Palvella Therapeutics, Inc. Files 8-K, Confirms Name Change — Sep 3, 2025 Risk: low
  On September 3, 2025, PALVELLA THERAPEUTICS, INC. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing indicates a name change from Pieris Ph
• Palvella Therapeutics Files 8-K on Security Holder Vote Matters — Jun 11, 2025 Risk: low
  On June 10, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report detailing a submission of matters to a vote of securit
• Palvella Therapeutics Files 8-K — Mar 4, 2025 Risk: low
  On March 4, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statements an
• Palvella Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  On January 13, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily concerns financial statements
• Palvella Therapeutics, Inc. Renamed, Completes Business Combination — Dec 16, 2024 Risk: medium
  On December 13, 2024, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) announced a change in its corporate name and ticker symbol. This follo
• Pieris Pharmaceuticals Files 8-K with Corporate Updates — Dec 12, 2024 Risk: medium
  Pieris Pharmaceuticals, Inc. filed an 8-K on December 12, 2024, reporting several key events as of December 11, 2024. These include material modifications to se
• Pieris Pharmaceuticals Files 8-K — Dec 3, 2024 Risk: low
  Pieris Pharmaceuticals, Inc. filed an 8-K on December 3, 2024, reporting on events that occurred on December 2, 2024. The filing indicates a submission of matte
• Pieris Pharmaceuticals Files 8-K — Oct 3, 2024 Risk: low
  Pieris Pharmaceuticals, Inc. filed an 8-K on October 3, 2024, reporting other events and financial statements. The filing does not contain specific details abou
• Pieris Pharmaceuticals Files 8-K: Agreements and Shareholder Rights Changes — Aug 8, 2024 Risk: medium
  On August 7, 2024, Pieris Pharmaceuticals, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company als
• Pieris Pharmaceuticals Files 8-K: Agreements, Equity Sales, and Officer Changes — Jul 24, 2024 Risk: medium
  On July 23, 2024, Pieris Pharmaceuticals, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The co
• Pieris Pharmaceuticals Terminates Material Agreement — Jul 3, 2024 Risk: medium
  On June 28, 2024, Pieris Pharmaceuticals, Inc. reported the termination of a material definitive agreement. The company also filed financial statements and exhi
• Seagen to Acquire Pieris Pharmaceuticals for $1.7 Billion — May 9, 2024 Risk: low
  Pieris Pharmaceuticals, Inc. announced on May 7, 2024, that it entered into a definitive agreement to be acquired by Seagen Inc. for $20.00 per share in cash, t
• Pieris Pharmaceuticals Files 8-K with Key Updates — Apr 18, 2024 Risk: medium
  Pieris Pharmaceuticals, Inc. filed an 8-K on April 18, 2024, to report material modifications to rights of security holders, amendments to its articles of incor
• Pieris Pharmaceuticals Files 8-K — Mar 27, 2024 Risk: medium
  Pieris Pharmaceuticals, Inc. filed an 8-K on March 27, 2024, reporting on its results of operations, other events, and financial statements. The filing details

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX